BSEM — Biostem Technologies Income Statement
0.000.00%
Last trade - 00:00
- $159.61m
- $157.60m
- $16.69m
- 49
- 41
- 93
- 63
R2016 December 31st | 2017 December 31st | 2020 December 31st | 2021 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | USG | USG | USG | USG | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.616 | 0.329 | 2.52 | 4.34 | 16.7 |
Cost of Revenue | |||||
Gross Profit | 0.222 | 0.179 | 1.25 | 2.82 | 15.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.74 | 5.16 | 4.36 | 5.14 | 23.8 |
Operating Profit | -3.13 | -4.83 | -1.84 | -0.802 | -7.16 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.2 | -4.86 | -2.37 | -1.41 | -7.86 |
Net Income After Taxes | -3.2 | -4.86 | -2.37 | -1.41 | -7.86 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -3.2 | -4.84 | -2.39 | -1.37 | -7.86 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.2 | -4.84 | -2.39 | -1.37 | -7.86 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.949 | -1.15 | -0.257 | -0.215 | -0.574 |